<SEC-DOCUMENT>0001213900-18-004068.txt : 20180404
<SEC-HEADER>0001213900-18-004068.hdr.sgml : 20180404
<ACCEPTANCE-DATETIME>20180404172224
ACCESSION NUMBER:		0001213900-18-004068
CONFORMED SUBMISSION TYPE:	S-8
PUBLIC DOCUMENT COUNT:		6
FILED AS OF DATE:		20180404
DATE AS OF CHANGE:		20180404
EFFECTIVENESS DATE:		20180404

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Wize Pharma, Inc.
		CENTRAL INDEX KEY:			0001218683
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880445167
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-8
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-224146
		FILM NUMBER:		18738215

	BUSINESS ADDRESS:	
		STREET 1:		5B HANAGAR STREET
		CITY:			HOD HASHARON
		STATE:			L3
		ZIP:			4527708
		BUSINESS PHONE:		972 472 260 0536

	MAIL ADDRESS:	
		STREET 1:		5B HANAGAR STREET
		CITY:			HOD HASHARON
		STATE:			L3
		ZIP:			4527708

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	OphthaliX, Inc.
		DATE OF NAME CHANGE:	20120207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DENALI CONCRETE MANAGEMENT INC
		DATE OF NAME CHANGE:	20030213
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-8
<SEQUENCE>1
<FILENAME>fs80418_wizepharma.htm
<DESCRIPTION>INITIAL REGISTRATION STATEMENT FOR SECURITIES TO BE OFFERED TO EMPLOYEES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">As filed with the Securities and Exchange Commission on
April 4, 2018&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Registration No. 333-____</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">WASHINGTON, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center">_______________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center">FORM S-8</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">REGISTRATION STATEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">UNDER</P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"><FONT STYLE="font-variant: normal">THE
SECURITIES ACT OF 1933</FONT></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"><FONT STYLE="font-variant: normal">_____________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>WIZE PHARMA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">(Exact name of registrant as specified
in its charter)</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 46%; padding-right: 5.4pt; padding-left: 5.4pt; border-bottom: Black 1pt solid"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-decoration: none; text-transform: none; text-align: center; vertical-align: baseline"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: baseline"><B>Delaware</B></FONT></P>
        <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 48.6pt 0 0; text-decoration: none; text-transform: none; text-align: center; vertical-align: baseline"></P></TD>
    <TD STYLE="width: 9%">&nbsp;</TD>
    <TD STYLE="width: 45%; padding-right: 5.4pt; padding-left: 5.4pt; font: bold 10pt Times New Roman, Times, Serif; text-decoration: none; text-transform: none; vertical-align: baseline; border-bottom: Black 1pt solid"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-decoration: none; text-transform: none; text-align: center; vertical-align: baseline"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: baseline"><B>88-0445167</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.55in; text-align: center"></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(State or Other Jurisdiction of Incorporation
        or Organization)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(I.R.S. Employer Identification Number)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><BR>
<B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>5b Hanagar Street, Hod Hasharon, Israel, 4527708</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Address of Principal Executive Offices; Zip
Code)</P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"><FONT STYLE="font-variant: normal">_______________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Wize Pharma, Inc. 2018 Stock Incentive Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Full Title of the Plan)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center">_______________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Or Eisenberg</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Acting CEO and CFO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Wize Pharma, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>5b Hanagar Street</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Hod Hasharon, Israel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>4527708</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Name and Address of Agent for Service)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>+972 (72) 260-0536</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Telephone Number, Including Area Code, of
Agent for Service)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth
company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting
company,&rdquo; and &quot;emerging growth company&quot; in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 40%">Large accelerated filer&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;&#9744;</TD>
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 26%">Accelerated filer&nbsp;</TD>
    <TD STYLE="width: 25%">&nbsp;&#9744;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Non-accelerated filer</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Smaller reporting company</TD>
    <TD>&nbsp;&#9746;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>(Do not check if a smaller reporting
company)</TD>
    <TD>&nbsp;&#9744;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Emerging growth company</TD>
    <TD>&nbsp;&#9746;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act<FONT STYLE="font-size: 10pt">. &#9746;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CALCULATION OF REGISTRATION FEE</B></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1.5pt solid">Title of Each Class of Securities to be Registered</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Amount</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>to be Registered (1)</B></P></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Proposed Maximum Offering Price Per Share (2)</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Proposed Maximum Aggregate Offering Price (2)</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount of Registration Fee (3)</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0.1in">Common Stock, $0.001 par value</TD><TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">435,052</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; font-variant: small-caps; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; font-size: 10pt; font-variant: small-caps; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; font-size: 10pt; font-variant: small-caps; text-align: right">3.74</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font-size: 10pt; font-variant: small-caps; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">1,627,094.48</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">202.57</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font-size: 10pt; text-align: left">(4)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">Pursuant
                                         to Rule 416(a) under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;),
                                         there are also being registered hereby an additional indeterminate number of shares of
                                         the Registrant&rsquo;s Common Stock, $0.001 par value (the &ldquo;Common Stock&rdquo;)
                                         as may become issuable to the selling stockholders as a result of stock splits, stock
                                         dividends and similar transactions, and, in any such event, the number of shares registered
                                         hereby shall be automatically increased to cover the additional share.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">The proposed
                                         maximum offering price per share and the proposed maximum aggregate offering price have
                                         been estimated solely for the purpose of calculating the amount of the registration fee
                                         in accordance with Rules 457(c) and 457(h) under the Securities Act, based on the average
                                         of the high and low closing prices of our Common Stock on April 3, 2018, as reported
                                         on the OTCQB, a date within five (5) business days prior to the date of this Registration
                                         Statement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(3)</TD><TD STYLE="text-align: justify">Determined in accordance with Section 6(b) of the Securities Act at a rate
equal to $124.50 per $1 million of the proposed maximum aggregate offering price.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(4)</TD><TD STYLE="text-align: justify">The Registration Fee is being offset against a portion of the fee paid by
the Company upon the filing of a Registration Statement on Form S-1 on February 6, 2018, as a result of the Company&rsquo;s reverse
stock split of its Common Stock at a ratio of one for twenty-four (1:24) which was effected on March 5, 2018.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>This Registration Statement shall become effective immediately
upon filing as provided in Rule 462 under the Securities Act of 1933.</B></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">EXPLANATORY NOTE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">As used in this Registration Statement, the
terms &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; the &ldquo;Company,&rdquo; &ldquo;Wize,&rdquo; &ldquo;our company&rdquo;
and the &ldquo;Registrant&rdquo; refer to Wize Pharma, Inc. (formerly known as OphthaliX, Inc.), a Delaware corporation. The references
to the &ldquo;Commission&rdquo; are to the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On February 22, 2018, the Board of Directors
approved the adoption of the 2018 Stock Incentive Plan (the &ldquo;2018 Plan&rdquo;), including the total number of shares of Common
Stock that may be subject to awards under the 2018 Plan (subject to appropriate adjustments in the case of stock splits, stock
dividends and similar recapitalization events, the &quot; Reserved Pool&quot;). As of the date hereof, the Reserved Pool is 435,052
shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The purpose of this Registration Statement on
Form S-8 is to register 435,052 shares of Common Stock for issuance under the 2018 Plan, all of which are reserved for issuance
under future stock options, shares of Common Stock, restricted stock and restricted stock units of our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">PART I</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">INFORMATION REQUIRED
IN THE SECTION 10(a) PROSPECTUS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><B>Item 1. Plan Information.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">The Company will provide
each recipient (the &ldquo;Recipients&rdquo;) of a grant under the 2018 Plan with documents that contain information related to
the Plan, and other information including, but not limited to, the disclosure required by Item 1 of Form S-8, which information
is not required to be and is not being filed as a part of this Registration Statement or as prospectuses or prospectus supplements
pursuant to Rule 424 under the Securities Act. The foregoing information and the documents incorporated by reference in response
to Item 3 of Part II of this Registration Statement, taken together, constitute a prospectus that meets the requirements of Section
10(a) of the Securities Act. A Section 10(a) prospectus will be given to each Recipient who receives common stock covered by this
Registration Statement, in accordance with Rule 428(b)(1) under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><B>Item 2. Registrant Information and Employee
Plan Annual Information.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">The Company will provide
to each Recipient a written statement advising of the availability of documents incorporated by reference in Item 3 of Part II
of this Registration Statement (which documents are incorporated by reference in this Section 10(a) prospectus) and of documents
required to be delivered pursuant to Rule 428(b) under the Securities Act without charge and upon written or oral request by contacting:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">Or Eisenberg</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">Acting Chief Executive
Officer and Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">Wize Pharma, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">5b Hanagar Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">Hod Hasharon, Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">4527708</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in; background-color: white">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid; text-align: center">1</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">PART II</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">INFORMATION REQUIRED IN THE REGISTRATION
STATEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Item 3. Incorporation of Documents by Reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 42.55pt">Wize hereby incorporates by reference
into this Registration Statement the following documents previously filed with the Commission:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.25pt"></TD><TD STYLE="width: 21.75pt">(a)</TD><TD>the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed with the Commission on March
29, 2018;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.25pt"></TD><TD STYLE="width: 21.75pt">(b)</TD><TD>The description of the Registrant&rsquo;s Common Stock incorporated herein by reference from the Company&rsquo;s Registration
Statement on Form S-4 filed with the Commission on July 27, 2017, and amended on September 5, 2017, including any amendment or
report filed for the purpose of updating such description; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.4pt"></TD><TD STYLE="width: 23.4pt">(c)</TD><TD>all other reports filed by the Registrant pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended
(the &ldquo;Exchange Act&rdquo;), since the end of the fiscal year covered by the documents referred to in clause (a) above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: left; text-indent: 0.5in">All documents subsequently
filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, and all Current Reports on Form 8-K submitted
to the Commission subsequent to the date hereof, to the extent that such Reports indicate that information therein is incorporated
by reference into the Registrant&rsquo;s Registration Statements on Form S-8, prior to the filing of a post-effective amendment
which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be
deemed to be incorporated by reference in this registration statement and to be part hereof from the date of filing of such documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 47.95pt">Any statement contained in a document
incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this
Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed
to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall
not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 4.&nbsp;&nbsp;&nbsp;Description of
Securities</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 5.&nbsp;&nbsp;&nbsp;Interests of Named
Experts and Counsel</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 6.&nbsp;&nbsp;&nbsp;Indemnification
of Directors and Officers</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35.45pt">As a corporation incorporated in the State
of Delaware, we are subject to the Delaware General Corporation Law (&ldquo;DGCL&rdquo;). Section&nbsp;102(b)(7) of the DGCL allows
a corporation to provide in its certificate of incorporation that a director of the corporation will not be personally liable to
the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except where the director
breached the duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized
the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal
benefit. Our charter provides for this limitation of liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35.45pt">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid; text-align: center">2</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35.45pt">&nbsp;Section&nbsp;145 of the DGCL (&ldquo;Section
145&rdquo;), provides, among other things, that a Delaware corporation may indemnify any person who was, is or is threatened to
be made, party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative
(other than an action by or in the right of such corporation), by reason of the fact that such person is or was an officer, director,
employee or agent of such corporation or is or was serving at the request of such corporation as a director, officer, employee
or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys&rsquo; fees), judgments,
fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding,
provided such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation&rsquo;s
best interests and, with respect to any criminal action or proceeding, had no reasonable cause to believe that his or her conduct
was unlawful. A Delaware corporation may indemnify any persons who were or are a party to any threatened, pending or completed
action or suit by or in the right of the corporation by reason of the fact that such person is or was a director, officer, employee
or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys&rsquo; fees) actually and
reasonably incurred by such person in connection with the defense or settlement of such action or suit, provided such person acted
in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation&rsquo;s best interests,
provided further that no indemnification is permitted without judicial approval if the officer, director, employee or agent is
adjudged to be liable to the corporation. Where an officer or director is successful on the merits or otherwise in the defense
of any action referred to above, the corporation must indemnify him or her against the expenses (including attorneys&rsquo; fees)
which such officer or director has actually and reasonably incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35.45pt">Section&nbsp;145 further authorizes a corporation
to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation
or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or enterprise,
against any liability asserted against such person and incurred by such person in any such capacity, or arising out of his or her
status as such, whether or not the corporation would otherwise have the power to indemnify such person under Section&nbsp;145.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35.45pt">Our charter and bylaws provide that we must
indemnify and advance expenses to its directors and officers to the full extent authorized by the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35.45pt">We expect to maintain standard policies of
insurance that provide coverage (1)&nbsp;to our directors and officers against loss arising from claims made by reason of breach
of duty or other wrongful act as defined in the policy and (2)&nbsp;to us with respect to indemnification payments that we may
make to such directors and officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35.45pt">The indemnification rights set forth above
shall not be exclusive of any other right which an indemnified person may have or hereafter acquire under any statute, any provision
of our charter, bylaws, agreement, vote of stockholders or disinterested directors or otherwise. Notwithstanding the foregoing,
we shall not be obligated to indemnify a director or officer in respect of a proceeding (or part thereof) instituted by such director
or officer, unless such proceeding (or part thereof) has been authorized by our board of directors pursuant to the applicable procedure
outlined in our bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35.45pt">Section&nbsp;174 of the DGCL provides, among
other things, that a director, who willfully or negligently approves of an unlawful payment of dividends or an unlawful stock purchase
or redemption, may be held jointly and severally liable for such actions. A director who was either absent when the unlawful actions
were approved or dissented at the time may avoid liability by causing his or her dissent to such actions to be entered in the books
containing the minutes of the meetings of the board of directors at the time such action occurred or immediately after such absent
director receives notice of the unlawful acts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 7.&nbsp;&nbsp;&nbsp;Exemption from
Registration Claimed</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Not applicable.</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid; text-align: center">3</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Item 8. Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><FONT STYLE="font-weight: normal">The following exhibits
are filed as part of this registration statement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid; vertical-align: top"><B>EXHIBIT NO.</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; text-align: left; vertical-align: top"><B>DESCRIPTION</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 12%; font-size: 10pt; text-align: left; vertical-align: top">3.1</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000107878212000959/f8k040512_ex3z1.htm" STYLE="-sec-extract: exhibit">Certificate of Incorporation (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the Commission on April 5, 2012)</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">3.2</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000107878213001371/f8k071813_ex3z1.htm" STYLE="-sec-extract: exhibit">Certificate of Amendment to Certificate of Incorporation (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the Commission on July 18, 2013)</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">3.3</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390017012449/f8k111517ex3-3_wizepharma.htm" STYLE="-sec-extract: exhibit">Certificate of Amendment to Certificate of Incorporation dated November 15, 2017 (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the Commission on November 21, 2017)</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">3.4</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390018002556/f8k030118ex3-1_wizepharma.htm" STYLE="-sec-extract: exhibit">Certificate of Amendment to Certificate of Incorporation dated March 1, 2018 (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the Commission on March 5, 2018)</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">3.5</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000107878213000919/f8k051013_ex3z1.htm" STYLE="-sec-extract: exhibit">Bylaws (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the Commission on May 10, 2013)</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">4.1</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390018001336/fs12018ex4-1_wizepharma.htm" STYLE="-sec-extract: exhibit">Specimen Common Stock Certificate (Incorporated by reference to Company&rsquo;s Registration Statement on Form S-1 filed with the Commission on February 6, 2018)</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">4.2</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390018002393/f8k022218ex10-1_wizepharma.htm" STYLE="-sec-extract: exhibit">Wize Pharma, Inc. 2018 Equity Incentive Plan (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the Commission on February 28, 2018)</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">5.1</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="fs80418ex5-1_wizepharma.htm">Opinion of Sichenzia Ross Ference Kesner LLP*</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">23.1</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="fs80418ex5-1_wizepharma.htm">Consent of Sichenzia Ross Ference Kesner LLP (contained in Exhibit 5.1)</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">23.2</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="fs80418ex23-2_wizepharma.htm">Consent of Fahn Kanne &amp; Co. Grant Thornton Israel*</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">24.1</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="fs80418ex23-2_wizepharma.htm">Powers of Attorney (included in the signature page to this Registration Statement)</A></TD></TR>
</TABLE>


<P STYLE="margin: 0">___________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in">* Filed herewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid; text-align: center">4</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 9. Undertakings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The undersigned Registrant hereby undertakes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(1)&nbsp;To file, during any period in which offers or sales are
being made, a post-effective amendment to this Registration Statement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">i.&nbsp;To include any prospectus required by
section 10(a)(3) of the Securities Act of 1933;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">ii. To reflect in the prospectus any facts or
events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which,
individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding
the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would
not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be
reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume
and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the &ldquo;Calculation
of Registration Fee&rdquo; table in the effective Registration Statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">iii.&nbsp;To include any material information
with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such
information in the Registration Statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>provided, however</I>, that paragraphs (1)(i)
and (1)(ii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs
is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or 15(d) of the Exchange
Act that are incorporated by reference in the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(2) That, for the purpose of determining any liability under the
Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities
offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(3)&nbsp;To remove from registration by means of a post-effective
amendment any of the securities being registered which remain unsold at the termination of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(4)&nbsp;The undersigned Registrant hereby undertakes that, for
purposes of determining any liability under the Securities Act, each filing of the registrant&rsquo;s annual report pursuant to
Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&rsquo;s annual report
pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed
to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time
shall be deemed to be the initial bona fide offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(5)&nbsp;Insofar as indemnification for liabilities arising under
the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing
provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against
public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling
person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or
controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel
the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><BR STYLE="clear: both">
</P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid; text-align: center">5</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center">SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Pursuant to the
requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form S-8 and has duly caused this registration statement on Form S-8 to be signed on its behalf
by the undersigned, thereunto duly authorized, in the City of Hod Hasharon, Israel, on the 4<SUP>th</SUP> day of April, 2018.</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2"><B>WIZE PHARMA, INC.</B></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="width: 6%">By:&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 35%">/s/ Or Eisenberg</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>Name:<BR>
Title:</TD>
    <TD STYLE="vertical-align: top; border-top: #000000 1px solid">Or Eisenberg<BR>Acting Chief Executive Officer, Chief&nbsp;Financial&nbsp;Officer, Treasurer and&nbsp;Secretary</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in"><B><A NAME="poa"></A>POWER OF ATTORNEY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Each of the undersigned officers and directors
of Wize Pharma, Inc., a Delaware corporation, hereby constitutes and appoints Or Eisenberg and Noam Danenberg and each of them,
severally, as his or her attorney-in-fact and agent, with full power of substitution and resubstitution, in his or her name and
on his or her behalf, to sign in any and all capacities this registration statement and any and all amendments (including post-effective
amendments) and exhibits to this registration statement and any and all applications and other documents relating thereto, with
the Securities and Exchange Commission, with full power and authority to perform and do any and all acts and things whatsoever
which any such attorney or substitute may deem necessary or advisable to be performed or done in connection with any or all of
the above described matters, as fully as each of the undersigned could do if personally present and acting, hereby ratifying and
approving all acts of any such attorney or substitute.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the
dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 180.6pt; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Signature</FONT></TD>
    <TD STYLE="width: 179.55pt; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Title</FONT></TD>
    <TD STYLE="width: 11.8pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 101.65pt; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Date</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">/s/ Or Eisenberg</P></TD>
    <TD ROWSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Acting Chief Executive Officer, Chief&nbsp;Financial&nbsp;Officer, Treasurer and&nbsp;Secretary</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD ROWSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;April 4, 2018</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Or Eisenberg</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">/s/ Ron Mayron</FONT></TD>
    <TD ROWSPAN="3" STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">Chairman of the Board</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P></TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD ROWSPAN="2" STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">April 4, 2018</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Ron Mayron</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">/s/ Yossi Keret</FONT></TD>
    <TD ROWSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD ROWSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">April 4, 2018</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Yossi Keret</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">/s/ Franck Amouyal</FONT></TD>
    <TD ROWSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Director </FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD ROWSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">April 4, 2018</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Franck Amouyal</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">/s/ Joseph Zarzewsky</FONT></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Director </FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">April 4, 2018</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Joseph Zarzewsky</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">/s/ Michael Belkin</P></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Director </FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">April 4, 2018</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Michael Belkin</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid; text-align: center">6</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid; vertical-align: top"><B>EXHIBIT NO.</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; text-align: left; vertical-align: top"><B>DESCRIPTION</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 12%; font-size: 10pt; text-align: left; vertical-align: top">3.1</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000107878212000959/f8k040512_ex3z1.htm" STYLE="-sec-extract: exhibit">Certificate of Incorporation (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the Commission on April 5, 2012)</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">3.2</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000107878213001371/f8k071813_ex3z1.htm" STYLE="-sec-extract: exhibit">Certificate of Amendment to Certificate of Incorporation (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the Commission on July 18, 2013)</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">3.3</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390017012449/f8k111517ex3-3_wizepharma.htm" STYLE="-sec-extract: exhibit">Certificate of Amendment to Certificate of Incorporation dated November 15, 2017 (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the Commission on November 21, 2017)</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">3.4</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390018002556/f8k030118ex3-1_wizepharma.htm" STYLE="-sec-extract: exhibit">Certificate of Amendment to Certificate of Incorporation dated March 1, 2018 (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the Commission on March 5, 2018)</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">3.5</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000107878213000919/f8k051013_ex3z1.htm" STYLE="-sec-extract: exhibit">Bylaws (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the Commission on May 10, 2013)</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">4.1</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390018001336/fs12018ex4-1_wizepharma.htm" STYLE="-sec-extract: exhibit">Specimen Common Stock Certificate (Incorporated by reference to Company&rsquo;s Registration Statement on Form S-1 filed with the Commission on February 6, 2018)</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">4.2</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390018002393/f8k022218ex10-1_wizepharma.htm" STYLE="-sec-extract: exhibit">Wize Pharma, Inc. 2018 Equity Incentive Plan (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the Commission on February 28, 2018)</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">5.1</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="fs80418ex5-1_wizepharma.htm">Opinion of Sichenzia Ross Ference Kesner LLP*</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">23.1</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="fs80418ex5-1_wizepharma.htm">Consent of Sichenzia Ross Ference Kesner LLP (contained in Exhibit 5.1)</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">23.2</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="fs80418ex23-2_wizepharma.htm">Consent of Fahn Kanne &amp; Co. Grant Thornton Israel*</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">24.1</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="fs80418ex23-2_wizepharma.htm">Powers of Attorney (included in the signature page to this Registration Statement)</A></TD></TR>
</TABLE>


<P STYLE="margin: 0">___________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in">* Filed herewith.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right"></P>

<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">7</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right"><BR STYLE="clear: both"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>fs80418ex5-1_wizepharma.htm
<DESCRIPTION>OPINION AND CONSENT OF SICHENZIA ROSS FERENCE KESNER LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 5%"><IMG SRC="image_006.jpg" ALT="" STYLE="width: 34px; height: 884px">&nbsp;</TD>
    <TD STYLE="width: 95%"><IMG SRC="image_007.jpg" ALT=""><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>
                                                           <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">April 4, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>VIA ELECTRONIC TRANSMISSION</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">100 F Street, N.E.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Washington, DC 20549</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Re: <U>Wize Pharma, Inc. Form S-8 Registration
Statement</U></P>
&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">We refer to the above-captioned
registration statement on Form S-8 (the &ldquo;Registration Statement&rdquo;) under the Securities Act of 1933, as amended (the
&ldquo;Act&rdquo;), filed by Wize Pharma, Inc., a Delaware corporation (the &ldquo;Company&rdquo;), with the Securities and Exchange
Commission, registering the offer and sale from time to time pursuant to the Company&rsquo;s 2018 Stock Incentive Plan of up to
435,052 shares of the Company&rsquo;s common stock, $0.001 par value per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">We have examined the
originals, photocopies, certified copies or other evidence of such records of the Company, certificates of officers of the Company
and public officials, and other documents as we have deemed relevant and necessary as a basis for the opinion hereinafter expressed.
In such examination, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as certified
copies or photocopies and the authenticity of the originals of such latter documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">Based on our examination
mentioned above, we are of the opinion that the securities being issued pursuant to the Registration Statement are duly authorized
and will be, when so issued, legally and validly issued, and fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">We hereby consent to
the filing of this opinion as Exhibit 5.1 to the Registration Statement. In giving the foregoing consent, we do not hereby admit
that we are in the category of persons whose consent is required under Section 7 of the Act, or the rules and regulations of the
Securities and Exchange Commission.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 65%; text-align: left">Very truly yours,</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 35pt 0 0; text-align: right">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 65%; text-align: left"><I>/s/&nbsp;Sichenzia
Ross Ference Kesner LLP</I></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-left: 65%; margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 75%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 65%; text-align: left"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 65%; text-align: left">Sichenzia
Ross Ference Kesner LLP</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 250pt; text-align: left"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 250pt; text-align: left">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 250pt; text-align: left">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 250pt; text-align: left">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 250pt; text-align: left">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 250pt; text-align: left">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 250pt; text-align: left">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 250pt; text-align: left">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 250pt; text-align: left">&nbsp;&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">1185
Avenue of the Americas <FONT STYLE="color: #548DD4">| </FONT>37<SUP>th</SUP> Floor <FONT STYLE="color: #548DD4">|</FONT> New York,
NY <FONT STYLE="color: #548DD4">|</FONT> 10036</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">T (212)
930 9700 <FONT STYLE="color: #548DD4">|</FONT> F (212) 930 9725 <FONT STYLE="color: #548DD4">| <B>WWW.SRFKLLP.COM</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: left">&nbsp;<I></I></P> </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>3
<FILENAME>fs80418ex23-2_wizepharma.htm
<DESCRIPTION>CONSENT OF FAHN KANNE & CO. GRANT THORNTON ISRAEL
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right"><B>Exhibit 23.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;<IMG SRC="image_002.jpg" ALT=""><FONT STYLE="font-size: 10pt">&nbsp;</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CONSENT OF INDEPENDENT<BR>
REGISTERED PUBLIC ACCOUNTING FIRM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We have issued our report dated March 28, 2018 with respect to the
consolidated financial statements of Wize Pharma, Inc. included in the Annual Report on Form 10-K for the year ended December 31,
2017, which is incorporated by reference in this Registration Statement. We consent to the incorporation by reference of the aforementioned
report in this Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">/s/ FAHN KANNE &amp; CO. GRANT THORNTON ISRAEL</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Tel-Aviv, Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date April 4, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Certified Public Accountants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Fahn Kanne &amp; Co. is the Israeli member firm of Grant Thornton
International Ltd.</P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !, 3,# 2(  A$! Q$!_\0
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M\4=7OO&@\)^*]"73-2D4M"8F(4D+NP02<@@'!!.<5ZM0 4444 %!HHH \?\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 57 "(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#HZ***L@/X
ME^M?>GP2_P"29Z+_ -<S_.O@O^)?K7WI\$O^29Z+_P!<S_.DQH[FBBBI*/S2
MHHHJR _B7ZU]Z?!+_DF>B_\ 7,_SKX+_ (E^M?>GP2_Y)GHO_7,_SI,:.YHH
MHJ2C\TJ***L@/XE^M?>GP2_Y)GHO_7,_SKX+_B7ZU]Z?!+_DF>B_]<S_ #I,
M:.YHHHJ2C\TJ***L@/XE^M?>GP2_Y)GHO_7,_P Z^"_XE^M?>GP2_P"29Z+_
M -<S_.DQH[FBBBI*/S2HHHJR _B7ZU]Z?!+_ ))GHO\ US/\Z^"U^^GUK[U^
M"O\ R3/1?^N?]:3*1W%%%%2,_-*BBBK(!?OI]:^]?@K_ ,DST7_KG_6O@I?O
MI]:^]?@K_P DTT7_ *YG^=)E([BBBBI&?FE1115D /OI]:^]?@I_R3/1?^N9
M_G7P4OWT^M?>OP5_Y)GHO_7/^M)E([BBBBI&?FE1115D OWT^M?>OP5_Y)GH
MO_7/^M?!7\2_6OO3X)?\DST7_KF?YTF4CN:***D9^:5%%%60'\2_6OO3X)?\
MDST7_KF?YU\%_P 2_6OO3X)?\DST7_KF?YTF-'<T445)1^:5%%%60'\2_6OO
M3X)?\DST7_KF?YU\%_Q+]:^]/@E_R3/1?^N9_G28T=S1114E'YI44459 ?Q+
M]:^]/@E_R3/1?^N9_G7P7_$OUK[T^"7_ "3/1?\ KF?YTF-'<T445)1^:5%%
M%60'\2_6OO3X)?\ ),]%_P"N9_G7P7_$OUK[T^"7_),]%_ZYG^=)C1W-%%%2
M4?FE1115D!_$OUK[T^"7_),]%_ZYG^=?!?\ $OUK[T^"7_),]%_ZYG^=)C1W
M-%%%24?FE1115D!_$OUK[T^"7_),]%_ZYG^=?!?\2_6OO3X)?\DST7_KF?YT
MF-'<T445)1^:5%%%60'\2_6OO3X)?\DST7_KF?YU\%_Q+]:^]/@E_P DST7_
M *YG^=)C1W-%%%24?FE1115D!_$OUK[T^"7_ "3/1?\ KF?YU\%_Q+]:^]/@
ME_R3/1?^N9_G28T=S1114E'YI44459 ?Q+]:^]/@E_R3/1?^N9_G7P7_ !+]
M:^]/@E_R3/1?^N9_G28T=S1114E'YI44459 ?Q+]:^]/@E_R3/1?^N9_G7P7
M_$OUK[T^"7_),]%_ZYG^=)C1W-%%%24?FE1115D!_$OUK[T^"7_),]%_ZYG^
M=?!?\2_6OO3X)?\ ),]%_P"N9_G28T=S1114E'YI44459 ?Q+]:^]/@E_P D
MST7_ *YG^=?!?\2_6OO3X)?\DST7_KF?YTF-'<T445)1^:5%%%60'\2_6OO3
MX)?\DST7_KF?YU\%_P 2_6OO3X)?\DST7_KF?YTF-'<T445)1^:5%%%60'\2
M_6OO3X)?\DST7_KF?YU\%_Q+]:^]/@E_R3/1?^N9_G28T=S1114E'YI44459
M ?Q+]:^]/@E_R3/1?^N9_G7P7_$OUK[T^"7_ "3/1?\ KF?YTF-'<T445)1^
M:5%%%60'\2_6OO3X)?\ ),]%_P"N9_G7P7_$OUK[T^"7_),]%_ZYG^=)C1W-
M%%%24?FE1115D!_$OUK[T^"7_),]%_ZYG^=?!?\ $OUK[T^"7_),]%_ZYG^=
M)C1W-%%%24?FE1115D!_$OUK[T^"7_),]%_ZYG^=?!?\2_6OO3X)?\DST7_K
MF?YTF-'<T445)1^:5%%%60'\2_6OO3X)?\DST7_KF?YU\%_Q+]:^]/@E_P D
MST7_ *YG^=)C1W-%%%24?FE1115D!_$OUK[T^"7_ "3/1?\ KF?YU\%_Q+]:
M^]/@E_R3/1?^N9_G28T=S1114E'YI44459 ?Q+]:^]/@E_R3/1?^N9_G7P7_
M !+]:^]/@E_R3/1?^N9_G28T=S1114E'YI44459 ?Q+]:^]/@E_R3/1?^N9_
MG7P7_$OUK[T^"7_),]%_ZYG^=)C1W-%%%24?FE1115D!_$OUK[T^"7_),]%_
MZYG^=?!?\2_6OO3X)?\ ),]%_P"N9_G28T=S1114E'YI44459 ?Q+]:^]/@E
M_P DST7_ *YG^=?!?\2_6OO3X)?\DST7_KF?YTF-'<T445)1^:5%%%60'\2_
M6OO3X)?\DST7_KF?YU\%_P 2_6OO3X)?\DST7_KF?YTF-'<T445)1^:5%%%6
M0'\2_6OO3X)?\DST7_KF?YU\%_Q+]:^]/@E_R3/1?^N9_G28T=S1114E'YI4
M4459 ?Q+]:^]/@E_R3/1?^N9_G7P7_$OUK[T^"7_ "3/1?\ KF?YTF-'<T44
M5)1\9>-/V9?$7AJV>[TZ:/6;=1EDA7#)7D,\,MK*T4\3PR*<%9%*G/XU^B@8
MKTKEO&7PQ\-^/(F&IV$8N2,"ZC&'7\!5BL?"0^\OUK[T^"7_ "3/1?\ KF?Y
MU\W_ ! _9HUKPW+]IT-FUBPSG8!F8?@*^EO@_8W.F_#O2;>[@>VN(T(:.088
M<TF".SHHHJ1F/17QU\(_^"A%CJMW%IWCZQ73Y)'Q_:=NNV%/3*]37UKX?\2:
M1XMTV*_T34K?4K2095X7!)_#K7?B<'7PCM6C;SZ?><F'Q='%*]*5S261D^Z2
MOT-6K)OF8LWYFJAR.N125Q'6:^]?[P_.BLC-%*P'XELH9B",UTO@?XD>*/AK
MJ27OAS6KG3I5/*JY96'I@FN;/WC17[1*,9KEDKH_(H2E!J479GV[\)?^"AQN
M)[73?'FD",L1$M]8@L[D]"PZ"OLW2=4MM=TJVU*R??:7"AHV]B,U^+-F/^)G
M8?\ 7PG\Z_8OX(1JWPLT$$#'D"O@\[P-#"J-2BK7Z=#[C)L96Q*E&L[\ITOX
MT5H?8X_>BOE+GTI^'9^\:*#]XT5^TGY"B2S_ .0G8?\ 7PG\Z_8SX'_\DMT'
M_K@*_'.S_P"0G8?]?"?SK]C/@?\ \DMT'_K@*^0XC_AT_4^MX?WJ?([NBBBO
M@S[$_#0_>-%!^\:*_:S\A1)9_P#(3L/^OA/YU^QGP/\ ^26Z#_UP%?CG9_\
M(3L/^OA/YU^QGP/_ .26Z#_UP%?(<1_PZ?J?6\/[U/D=W1117P9]B?AH?O&B
M@_>-%?M9^0HDL_\ D)V'_7PG\Z_8SX'_ /)+=!_ZX"OQSL_^0G8?]?"?SK]C
M/@?_ ,DMT'_K@*^0XC_AT_4^MX?WJ?([NBBBO@S[$_#0_>-%!^\:*_:S\A1)
M9_\ (3L/^OA/YU^QGP/_ .26Z#_UP%?CG9_\A.P_Z^$_G7[&? __ ));H/\
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M /)+=!_ZX"OD.(_X=/U/K>']ZGR.[HHHKX,^Q/PT/WC10?O&BOVL_(426?\
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M!_ZX"OD.(_X=/U/K>']ZGR.[HHHKX,^Q/PT/WC10?O&BOVL_(426?_(3L/\
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M]K/R%$EG_P A.P_Z^$_G7[&? _\ Y);H/_7 5^.=G_R$[#_KX3^=?L9\#_\
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MPT/WC10?O&BOVL_(426?_(3L/^OA/YU^QGP/_P"26Z#_ -<!7XYV?_(3L/\
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M_P"0G8?]?"?SK]C/@?\ \DMT'_K@*_'.S_Y"=A_U\)_.OV,^!_\ R2W0?^N
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$[$__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !N 0T# 2(  A$! Q$!_\0
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MI^T1X#\&V_@)=7T[Q%X7D%K:)=:<((_L+(%,8<.<%&2)E^C>M?I%^QK\;O\
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M?PM!'=0/ TMOH]O'(@92I*,$RK#/!'(-?,W[*'[*OQW_ &3;7Q7I>DZGX/\
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MK?\ ;R_S ^R/@W\!_ _P"\,MH/@?0H-&LI&$EQ(I,D]S(!C?+*Q+.?3)P,\
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MU?\ Q+\C@/B)=3V^K6RQ3R1*8<D1N5'WCZ5RO]I7G_/W<?\ ?UO\:Z7XE?\
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MFE(NO,,F0N^&/[NP9QG[PZ5^<'[#?[5]Y^R+H_BNVO?AOX@\3'7I+656M5:
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M_P :ZO5?$EAHLR17<C([KN 5"W&<=JI?\)YHW_/P_P#WZ;_"OBE?H?IY@_\
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MIEMI_$RV$ U26R7$#W7EKYQC'92^['M6<H.*3?4#<HHHJ /SO^&/_)2/"O\
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%44 ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
